Search research articles
Contact Us
Filters
Showing results (1-10 of 34) with videos related to
Page
of 4
Sort By:
Cognitive Neuropsychology
|
February 7, 2014
Losing control of your languages: a case study
Marco Calabria, Paula Marne, Lucía Romero-Pinel, et al.
International Archives of Allergy and Immunology
|
January 31, 2015
IgE-mediated allergic reactions after the first administration of glatiramer acetate in patients with multiple sclerosis
Mercè Corominas, Idoia Postigo, Victoria Cardona, et al.
Journal of Neurology
|
February 14, 2016
Absence of MxA induction is related to a poor clinical response to interferon beta treatment in multiple sclerosis patients
Elisabet Matas, Laura Bau, María Martínez-Iniesta, et al.
Plos One
|
November 15, 2014
Baseline MxA mRNA expression predicts interferon beta response in multiple sclerosis patients
Elisabet Matas, Laura Bau, María Martínez-Iniesta, et al.
European Neurology
|
March 21, 2015
Effectiveness of natalizumab in patients with highly active relapsing remitting multiple sclerosis
Álvaro Cobo-Calvo, Laura Bau, Elisabet Matas, et al.
Plos One
|
April 29, 2022
Cost associated with a relapse-free patient in multiple sclerosis: A real-world health indicator
Lucía Romero-Pinel, Laura Bau, Elisabet Matas, et al.
BMC Neurology
|
October 5, 2013
Idiopathic acute transverse myelitis: outcome and conversion to multiple sclerosis in a large series
Alvaro Cobo Calvo, M Alba Mañé Martínez, Agustí Alentorn-Palau, et al.
Journal of Neuroimmunology
|
February 10, 2016
MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients
Elisabet Matas, Laura Bau, María Martínez-Iniesta, et al.
Journal of the Neurological Sciences
|
September 3, 2010
Epistasis between HLA-DRB1 parental alleles in a Spanish cohort with multiple sclerosis
Lucía Romero-Pinel, Josep María Pujal, Sergio Martínez-Yélamos, et al.
Journal of Neurology
|
March 13, 2023
Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment
Albert Muñoz-Vendrell, Pablo Arroyo-Pereiro, Isabel León, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 34) with videos related to
Sort By:
Page
of 4
Cognitive Neuropsychology
|
February 7, 2014
Losing control of your languages: a case study
Marco Calabria, Paula Marne, Lucía Romero-Pinel, et al.
International Archives of Allergy and Immunology
|
January 31, 2015
IgE-mediated allergic reactions after the first administration of glatiramer acetate in patients with multiple sclerosis
Mercè Corominas, Idoia Postigo, Victoria Cardona, et al.
Journal of Neurology
|
February 14, 2016
Absence of MxA induction is related to a poor clinical response to interferon beta treatment in multiple sclerosis patients
Elisabet Matas, Laura Bau, María Martínez-Iniesta, et al.
Plos One
|
November 15, 2014
Baseline MxA mRNA expression predicts interferon beta response in multiple sclerosis patients
Elisabet Matas, Laura Bau, María Martínez-Iniesta, et al.
European Neurology
|
March 21, 2015
Effectiveness of natalizumab in patients with highly active relapsing remitting multiple sclerosis
Álvaro Cobo-Calvo, Laura Bau, Elisabet Matas, et al.
Plos One
|
April 29, 2022
Cost associated with a relapse-free patient in multiple sclerosis: A real-world health indicator
Lucía Romero-Pinel, Laura Bau, Elisabet Matas, et al.
BMC Neurology
|
October 5, 2013
Idiopathic acute transverse myelitis: outcome and conversion to multiple sclerosis in a large series
Alvaro Cobo Calvo, M Alba Mañé Martínez, Agustí Alentorn-Palau, et al.
Journal of Neuroimmunology
|
February 10, 2016
MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients
Elisabet Matas, Laura Bau, María Martínez-Iniesta, et al.
Journal of the Neurological Sciences
|
September 3, 2010
Epistasis between HLA-DRB1 parental alleles in a Spanish cohort with multiple sclerosis
Lucía Romero-Pinel, Josep María Pujal, Sergio Martínez-Yélamos, et al.
Journal of Neurology
|
March 13, 2023
Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment
Albert Muñoz-Vendrell, Pablo Arroyo-Pereiro, Isabel León, et al.
Page
of 4